Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Science educators from across the region gathered last month at the Impact Career Innovation Center on the Durango High ...
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR ...
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...
Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...
Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback